4D Molecular Therapeutics, Inc. (FDMT) – What Are Researchers Thinking About This Stock?

Shares of 4D Molecular Therapeutics, Inc. (NASDAQ:FDMT) have earned an average rating of “Moderate Buy” from the twelve analysts that are covering the company, MarketBeat.com reports. One analyst has rated the stock with a sell rating, one has given a hold rating and ten have given a buy rating to the company. The average 12 month price target among brokerages that have issued a report on the stock in the last year is $28.90.

A number of brokerages recently issued reports on FDMT. Chardan Capital lowered their price target on shares of 4D Molecular Therapeutics from $26.00 to $25.00 and set a “buy” rating on the stock in a report on Tuesday, October 6th. Bank of America lifted their price objective on shares of 4D Molecular Therapeutics from $29.00 to $33.00 and gave the company a “buy” rating in a report on Tuesday, September 29th. B. Riley Financial reaffirmed a “buy” rating on shares of 4D Molecular Therapeutics in a report on Monday, August 17th. HC Wainwright reiterated a “buy” rating and issued a $36.00 price objective on shares of 4D Molecular Therapeutics in a research report on Monday, July 20th. Finally, Weiss Ratings reiterated a “sell (d-)” rating on shares of 4D Molecular Therapeutics in a research report on Thursday.

Insider Activity at 4D Molecular Therapeutics

In related news, insider David Kirn sold 58,333 shares of 4D Molecular Therapeutics stock in a transaction dated Monday, October 5th. The stock was sold at an average price of $12.92, for a total value of $753,662.36. Following the completion of the transaction, the insider owned 709,153 shares in the company, valued at $9,162,256.76. The trade was a 7.60% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. In the last 90 days, insiders sold 134,570 shares of company stock worth $1,759,323. 7.90% of the stock is owned by company insiders.

Hedge Funds Weigh In On 4D Molecular Therapeutics

A number of large investors have recently bought and sold shares of the business. Sei Investments Co. lifted its position in 4D Molecular Therapeutics by 8.9% during the first quarter. Sei Investments Co. now owns 12,862 shares of the company’s stock worth $120,000 after buying an additional 1,050 shares in the last quarter. Toth Financial Advisory Corp acquired a new position in 4D Molecular Therapeutics during the third quarter worth $29,000. Headlands Technologies LLC grew its holdings in 4D Molecular Therapeutics by 20.6% in the 2nd quarter. Headlands Technologies LLC now owns 19,238 shares of the company’s stock valued at $256,000 after buying an additional 3,282 shares in the last quarter. Legal & General Group Plc purchased a new stake in 4D Molecular Therapeutics in the 2nd quarter valued at $59,000. Finally, Susquehanna Fundamental Investments LLC purchased a new stake in 4D Molecular Therapeutics in the 2nd quarter valued at $148,000. Institutional investors and hedge funds own 99.27% of the company’s stock.

4D Molecular Therapeutics Trading Up 1.2%

4D Molecular Therapeutics stock opened at $12.29 on Tuesday. The company has a current ratio of 8.03, a quick ratio of 8.03 and a debt-to-equity ratio of 0.05. 4D Molecular Therapeutics has a 12 month low of $6.96 and a 12 month high of $16.93. The stock’s 50 day simple moving average is $14.02 and its two-hundred day simple moving average is $11.55. The firm has a market cap of $678.90 million, a PE ratio of -4.67 and a beta of 2.75.

4D Molecular Therapeutics (NASDAQ:FDMT) last posted its earnings results on Thursday, August 13th. The company reported ($1.04) earnings per share for the quarter, missing the consensus estimate of ($1.02) by ($0.02). 4D Molecular Therapeutics had a negative net margin of 194.74% and a negative return on equity of 41.33%. The firm had revenue of $3.78 million for the quarter, compared to analysts’ expectations of $3.62 million. Analysts anticipate that 4D Molecular Therapeutics will post -4.14 earnings per share for the current year.

4D Molecular Therapeutics Company Profile

4D Molecular Therapeutics, Inc is a clinical-stage biotechnology company focused on developing gene therapies for serious diseases. The company uses its Therapeutic Vector Evolution platform to engineer adeno-associated virus (AAV) vectors designed to deliver genetic medicines to specific tissues, including the eye and lungs.

Its investigational pipeline includes 4D-150, an intravitreal gene therapy being developed for retinal diseases such as wet age-related macular degeneration and diabetic macular edema.